Week 08/29/2005 through 09/04/2005

Prepared by Capital Hunter analysts

This reporting period companies based in California operating in the biotechnology industry and that have raised their Series B round of financing led the pack in the amount of venture financing raised. There were no initial public offerings this week.

You can still submit your business plan to CapitalHunter.com, for a free review by our experienced staff of analysts and see if you qualify for investment capital. Also, if you want to advertise with our newsletter (circulation 20,000) call us at 619-236-9998 and we can make an arrangement suitable for you.

CapitalHunter.com was able to verify that $389 million of venture capital was invested in 36 U.S.-based companies during this week’s reporting period. The average deal size was approximately 10.81 million. The amount of venture capital invested this period increased by 27% compared to last periods $306 million.

Geographically, twenty California companies raised $200.92 million in new equity financing which represents 52% of the total venture capital invested this reporting period. The largest private venture financing in California this period was into TargeGen. TargeGen raised $30 million and is a San Diego based vascular biotechnology company developing therapeutics for cancer, cardiovascular, ocular, and inflammatory diseases.

The biotechnology sector raised 28% of the venture capital this period. Six biotechnology companies raised $111.02 million in venture financing. The largest private venture financing in the biotechnology sector this period was into Biolex Therapeutics. Biolex is a Pittsboro, North Carolina based biotechnology company currently developing complex proteins and monoclonal antibodies for medical use.

Companies raising their Series B round of financing led this week’s venture capital activity. Series B financings represented 40% of the total venture capital deployed this period. The largest private venture financing in Series B stage financing this period was also into Biolex Therapeutics.

The three largest venture deals this period are as follows:

The following twenty and other unnamed investors funded the above mentioned top three venture capital investments for $91 million:

A total of 66 equity financings of private and public companies occurred during this reporting period. Each of the 66 equity financings are profiled in a weekly report which include venture financings, private placements, secondary offerings, PIPE’s, and IPO’s.

About CapitalHunter.com

CapitalHunter.com is a web-based financial information company that identifies, preserves and electronically disseminates worldwide data on venture capital and other equity financings. Customers utilize the CapitalHunter.com searchable database to research newly and historic financings and to identify active investors.

Please visit www.capitalhunter.com and get immediate access. New subscribers can request a free investor analysis.

To be REMOVED from this free service, CLICK HERE